Gary Mo

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 2

Top Topics

Prognostic Factors

Stem Cell Transplantation

Radiation Therapy

Top Venues

Cancer medicine

Clinical pharmacokinetics

Eli Lilly and Company

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Eli Lilly and Company

United States

Research Scientist

Publications

Leo Mascarenhas, Chitose Ogawa, Theodore W Laetsch, Brenda J Weigel, Michael W Bishop, Julie I Krystal, Scott C Borinstein, Emily K Slotkin, Jodi A Muscal, Pooja Hingorani, Donna E Levy, Gary Mo, Ashwin Shahir, Jennifer Wright, Steven G DuBois
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer medicine 10 (3) (2021)
Gary Mo, John R Baldwin, Debra Luffer-Atlas, Robert L Ilaria, Ilaria Conti, Michael Heathman, Damien M Cronier
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer. Clinical pharmacokinetics 57 (3) (2019)